TY - JOUR T1 - [Effect of somatostatin on splanchnic hemodynamics in liver cirrhosis]. AU - Merkel,C, AU - Gatta,A, AU - Zuin,R, AU - Finucci,G F, AU - Arnaboldi,L, AU - Ruol,A, PY - 1984/11/17/pubmed PY - 1984/11/17/medline PY - 1984/11/17/entrez SP - 2673 EP - 8 JF - Minerva medica JO - Minerva Med VL - 75 IS - 44 N2 - The effect of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis is not clearly defined, as some Authors reported a decrease in portal pressure and in liver blood flow during i.v. administration of this hormone, while others did not. In 19 subjects with liver cirrhosis and portal hypertension the following parameters were measured before and during i.v. infusion of somatostatin (7.5 micrograms/min): porto-hepatic gradient, effective hepatic plasma flow, specific splenic blood flow, cardiac output. Moreover the gastrin-G-17 plasma levels, those of insulin and growth hormone were measured. Effective hepatic plasma flow decreased significantly during somatostatin infusion (P less than 0.05), averaging a 15% decrease. Porto-hepatic gradient, specific splenic blood flow, cardiac output did not vary significantly. Gastrin, insulin and growth hormone plasma levels decreased significantly (P less than 0.02, 0.01, 0.05). These data indicate that somatostatin infused at the dose of 7.5 micrograms/min provokes endocrine effects, but as far as the splanchnic circulation is concerned, it induces a slight decrease in liver blood flow without affecting portal hypertension. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/6151151/[Effect_of_somatostatin_on_splanchnic_hemodynamics_in_liver_cirrhosis]_ L2 - https://medlineplus.gov/cirrhosis.html DB - PRIME DP - Unbound Medicine ER -